Although Japan has a reputation as a difficult market for new medical products to enter, the government and several public/private initiatives are making ground-breaking efforts to change that image. Several initiatives--some modeled after US Food & Drug Administration practices--will be launched in 2009. These changes, as well as others made in 2008, already are cutting into the drawn-out review times that manufacturers historically have had to face as a normal part of doing business in the country.
by Robert Neil
Attention medical device manufacturers: Japan is calling. Although the country has a reputation as a difficult market for new medical...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.
The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.
Medical device firms often have serious compliance gaps, a recent Veeva MedTech survey found. Only 50% of the companies surveyed are confident in their global registration data, with 70% reporting inconsistencies during audits. The report recommends automation and better data governance.
